...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Hepatology: Official Journal of the American Association for the Study of Liver Diseases >Durability of peginterferon alfa-2b treatment at 5 years in patients with hepatitis B e antigen-positive chronic hepatitis B.
【24h】

Durability of peginterferon alfa-2b treatment at 5 years in patients with hepatitis B e antigen-positive chronic hepatitis B.

机译：乙型肝炎e抗原阳性的慢性乙型肝炎患者接受聚乙二醇干扰素alfa-2b治疗5年的耐久性

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Approximately 30%-40% of patients with hepatitis B e antigen (HBeAg)-positive chronic hepatitis B treated with peginterferon and/or lamivudine achieve HBeAg seroconversion 6 months after the end of treatment. The durability and long-term effect of treatment are unknown. In this study, 85 HBeAg-positive patients who received peginterferon alfa-2b 1.5 microg/kg/week for 32 weeks and lamivudine 100 mg/day for 52 or 104 weeks were prospectively followed for 6.1 +/- 1.7 years posttreatment. Twenty-five (29%) patients had virologic response (HBeAg seroconversion and HBV DNA <10,000 copies/mL) at 5 years. The rate of HBeAg seroconversion rose progressively from 37% at the end of treatment to 60% at 5 years. Twenty-seven (32%) and 11 (13%) patients had undetectable HBV DNA (<100 copies/mL) at the end of peginterferon treatment and at 5 years, respectively. Two (2.4%) patients achieved hepatitis B surface antigen (HBsAg) seroclearance at 2.6 and 84 months posttreatment. Among virologic responders at the end of treatment, 82% and 57% and sustained HBeAg seroconversion and virologic response at 5 years. End-of-treatment serum quantitative HBsAg was significantly lower in patients with sustained virologic response at 5 years (median 1,431 IU/mL versus 2,689 IU/mL [P = 0.041]). At the last follow-up, the liver stiffness measurement by transient elastography was 5.8 +/- 2.7 kPa. Only two patients had liver stiffness suggestive of advanced fibrosis. Week 16 HBV DNA, end-of-treatment HBeAg seroconversion, and undetectable HBV DNA were independent factors associated with virologic response at 5 years. The duration of concomitant lamivudine treatment had no impact on any long-term response. CONCLUSION: Peginterferon has high durability in HBeAg-positive chronic hepatitis B patients with end-of-treatment virologic response.
机译：接受聚乙二醇干扰素和/或拉米夫定治疗的乙型肝炎e抗原（HBeAg）阳性的慢性乙型肝炎患者，约有30％-40％在治疗结束后6个月达到HBeAg血清转化。治疗的持久性和长期效果尚不清楚。在这项研究中，对接受peginterferon alfa-2b 1.5微克/千克/周，32周和拉米夫定100 mg /天，52或104周的85例HBeAg阳性患者进行了6.1 +/- 1.7年的前瞻性随访。 25岁（29％）的患者在5年内出现病毒学应答（HBeAg血清转化和HBV DNA <10,000拷贝/ mL）。 HBeAg血清转化率从治疗结束时的37％逐渐增加到5年时的60％。在聚乙二醇干扰素治疗结束时和第5年时，分别有27（32％）和11（13％）患者的HBV DNA检测不到（<100拷贝/ mL）。 2名（2.4％）患者在治疗后2.6和84个月时达到了乙型肝炎表面抗原（HBsAg）血清清除。在治疗结束后的病毒学应答者中，分别有82％和57％的患者在5年时持续出现HBeAg血清转化和病毒学应答。在5年持续病毒学应答的患者中，治疗结束时血清定量HBsAg显着降低（中位数为1,431 IU / mL，而中位数为2,689 IU / mL [P = 0.041]）。在最后一次随访中，通过瞬时弹性成像法测得的肝硬度为5.8 +/- 2.7 kPa。只有两名患者的肝脏僵硬提示晚期纤维化。第16周HBV DNA，治疗结束后的HBeAg血清转化和无法检测到的HBV DNA是与5年病毒学应答相关的独立因素。拉米夫定治疗的持续时间对任何长期反应均无影响。结论：聚乙二醇干扰素对HBeAg阳性的慢性乙型肝炎患者具有治疗后病毒学应答，具有较高的持久性。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号